Results 11 to 20 of about 2,579,690 (304)

Curing advanced melanoma by 2025 [PDF]

open access: yesCurrent Opinion in Oncology, 2015
PURPOSE OF REVIEW To outline the most urgent challenges in the management of advanced melanoma. RECENT FINDINGS Considerable progress in targeted and immunotherapy of advanced melanoma has opened a perspective for a cure if all molecular and medical information is integrated in a rational precision treatment algorithm. SUMMARY Bioinformatics and system
Dummer, Reinhard   +3 more
openaire   +7 more sources

TP63 is implicated in apoptotic dysregulation in melanoma [PDF]

open access: yes, 2010
PhDCutaneous melanoma is an aggressive malignancy accounting for 4% of skin cancers but 80% of all skin-cancer related deaths. Its incidence is rapidly rising and advanced disease is notoriously treatment-resistant.
Matin, Rubeta N H
core   +4 more sources

Advances in immunotherapy for melanoma [PDF]

open access: yesBMC Medicine, 2016
In recent years, the introduction and Federal Drug Administration approval of immune checkpoint inhibitor antibodies has dramatically improved the clinical outcomes for patients with advanced melanoma. These antagonist monoclonal antibodies are capable of unleashing dormant or exhausted antitumor immunity, which has led to durable complete and partial ...
Redman, Jason M.   +2 more
openaire   +2 more sources

Immunotherapy for Advanced Melanoma [PDF]

open access: yesJournal of Investigative Dermatology, 2008
Immunotherapy for melanoma has undergone significant change since the first attempts to treat patients with high dose IL-2. Herein, strategies to boost patient antitumor immunity through vaccination, treatment with agents that augment host immunity, and adoptive cell transfer will be discussed.
Fang, Lei   +2 more
openaire   +2 more sources

Advanced acral melanoma [PDF]

open access: yesJAAD Case Reports, 2015
In the United States, the incidence of melanoma is increasing faster than any other preventable cancer. Acral melanoma is the fourth most common type of cutaneous melanoma and is frequently diagnosed later in its course compared with melanoma in other anatomic locations. Here we describe a case of highly advanced acral melanoma.
Lambert Smith, Franki   +2 more
openaire   +2 more sources

Advances in immunotherapy for melanoma [PDF]

open access: yesMelanoma Management, 2014
Paolo A Ascierto obtained his MD from the University of Naples, Italy, where he earned board certification in oncology. He is currently Director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, National Tumor Institute 'Fondazione G. Pascale', Naples, Italy. Before his present position, he served consecutive positions there as
Paolo A, Ascierto, James, Larkin
openaire   +2 more sources

Biology of advanced uveal melanoma and next steps for clinical therapeutics [PDF]

open access: yes, 2014
Uveal melanoma is the most common intraocular malignancy although it is a rare subset of all melanomas. Uveal melanoma has distinct biology relative to cutaneous melanoma, with widely divergent patient outcomes.
Gutkind, JS   +17 more
core   +3 more sources

Advances in the treatment of melanoma [PDF]

open access: yesClinical Medicine, 2012
#### Key Points Melanoma incidence and mortality are increasing Melanoma is relatively resistant to therapy with standard chemotherapeutic regimens The small molecule inhibitor vemurafenib that targets melanomas with a common and specific mutation (BRAF V600E) has shown promise in the ...
Lacy, Katie E.   +2 more
openaire   +3 more sources

Advances in management of melanoma [PDF]

open access: yesAustralian and New Zealand Journal of Medicine, 1999
It is clear from the above that the sentinel node technique and assessment of circulating melanoma cells has provided important additional methods for staging and assessment of prognosis of patients with melanoma. Cure of the disease still depends on good quality surgery and implementation of quality control measures to ensure the adequacy of surgical ...
openaire   +2 more sources

Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection

open access: yesFrontiers in Medicine, 2019
Ipilimumab, in combination with nivolumab, is one of the promising drugs that enhance the anti-tumor immune response of patients with advanced melanoma. Since the co-administration of nivolumab with ipilimumab in the neoadjuvant setting expands melanoma ...
Taku Fujimura   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy